Form 4: IOVANCE BIOTHERAPEUTICS Interim CEO & General Counsel Reports Vesting of Over 52,000 Restricted Stock Units

Frederick G. Vogt, Interim CEO and General Counsel of IOVANCE BIOTHERAPEUTICS, reported the vesting of 52,085 restricted stock units and the subsequent withholding of 22,127 shares for tax purposes, resulting in a net increase in his direct common stock holdings.

Summary

• Frederick G. Vogt, Interim CEO & General Counsel of IOVANCE BIOTHERAPEUTICS, reported transactions on June 2, 2025.
• 52,085 shares of common stock were acquired upon the vesting of restricted stock units (RSUs).
• Concurrently, 22,127 shares were disposed of (withheld by the Issuer) to satisfy mandatory tax withholding requirements related to the RSU vesting, at a price of $1.76 per share.
• Following these transactions, Mr. Vogt directly beneficially owns 404,604 shares of common stock.
• Additionally, 10,417 RSUs granted on March 2, 2023, and 41,668 RSUs granted on March 1, 2024, vested and were converted into common stock.
• Mr. Vogt retains 31,252 RSUs from the March 2, 2023 grant and 291,682 RSUs from the March 1, 2024 grant, with remaining RSUs scheduled to vest in equal quarterly installments.

Sentiment

Score: 7

Explanation: The document reports a routine, expected insider transaction (RSU vesting) which is a positive sign of executive compensation and alignment. There are no negative surprises or red flags, and the executive retains a substantial equity stake.

Positives

• The vesting of restricted stock units indicates the fulfillment of pre-scheduled compensation agreements for the Interim CEO & General Counsel.
• The retention of a significant number of common shares (404,604) and remaining RSUs (322,934) by a key executive demonstrates continued alignment of interests with shareholders.

Negatives

• A portion of the vested shares (22,127 shares) was withheld for tax purposes, which is a common practice but reduces the net shares received by the executive.

Future Outlook

The document indicates that remaining Restricted Stock Units (RSUs) held by Frederick G. Vogt will continue to vest in equal quarterly installments, suggesting ongoing executive compensation through equity.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of restricted stock units. Such transactions are common across all industries, including the biotechnology sector where IOVANCE BIOTHERAPEUTICS operates, as a standard component of long-term incentive plans designed to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The vesting and retention of shares by a key executive like the Interim CEO & General Counsel can be viewed positively as it aligns management's interests with shareholder value. The tax withholding is a standard operational aspect of equity compensation.
• Employees: This filing pertains to executive compensation and does not directly impact the broader employee base, though it reflects the company's equity compensation practices.
• Creditors/Suppliers/Customers: No direct impact on these stakeholders as the filing is about internal share ownership changes.

Next Steps

• Remaining Restricted Stock Units (RSUs) held by Frederick G. Vogt are scheduled to vest in equal quarterly installments.

Key Dates

Recommendation

Keywords

IOVANCE BIOTHERAPEUTICS, IOVA, Frederick G. Vogt, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Executive Compensation, Share Ownership